Investors Press Releases Cardiol Therapeutics’ Exclusive Manufacturing Partner Receives Three-Year Renewal and Amendment of its Cannabis Act License from Health Canada January 15, 2020 Cardiol Therapeutics Appoints Michael J. Willner, Esq. as Business Advisor December 18, 2019 Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors December 03, 2019 Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency November 25, 2019 Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx™100 November 19, 2019 Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx™100 October 01, 2019 Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th September 05, 2019 Cardiol Therapeutics to Present at Canaccord Genuity 39th Annual Growth Conference July 29, 2019 Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation June 20, 2019 Cardiol Therapeutics Reports 2018 AGM Results June 13, 2019 Page 1 of 41234»
